AstraZeneca's Ultomiris achieved primary endpoint in Phase III trial, significantly reducing proteinuria in adults with IgA nephropathy.

On April 21st, AstraZeneca announced that the drug Ultomiris had met its primary endpoint in a Phase III clinical trial, with results showing that the drug significantly reduced proteinuria levels in adult patients with atypical hemolytic uremic syndrome at risk of disease progression. Ultomiris showed rapid reduction in proteinuria levels as early as week 10.